Sibutramine, a serotonin reuptake inhibitor, currently is used in treatment of obesity. The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects. We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman. We hypothesize that sibutramine, through its effect on neurotransmitters, may induce antidiuretic hormone secretion and lead to a syndrome of inappropriate antidiuretic hormone secretion. We advise careful monitoring of water-electrolytic balance during sibutramine therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.ajkd.2008.02.361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
Arch Endocrinol Metab
December 2024
Centro de Obesidade Hospital Nove de Julho São PauloSP Brasil Centro de Obesidade, Hospital Nove de Julho, São Paulo, SP, Brasil.
Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.
View Article and Find Full Text PDFEvaluation of Anti-obesity Potential of Leaves.
Arch Razi Inst
April 2024
Department of Biotechnology, KAHER's Dr. Prabhakar Kore Basic Science Research Centre, Belagavi-590010, Karnataka, India.
Obesity has been an important health concern for over a decade, causing serious health issues worldwide. Treatments available for obesity include FDA-approved drugs such as Lorcaserin, Orlistat, Bupropion, combinations of Phentermine and Topiramate, and Sibutramine; however, these have adverse effects on health. To address the said issue, the current study was conducted to evaluate the anti-obesity potential of leaves.
View Article and Find Full Text PDFThe history of anti-obesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.
View Article and Find Full Text PDFCharting New Territories in Obesity Management- Traditional Techniques to Tirzepatide.
Endocr Pract
January 2025
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
Background: Obesity, a pervasive global health challenge affecting more than 2 billion people, requires comprehensive interventions. Traditional approaches, including lifestyle modification, and diverse drugs targeting a gastrointestinal hormone, including glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (Liraglutide, Semaglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Orlistat, Phentermine/Topiramate, Lorcaserin, Sibutramine, and Rimonabant) offer tailored strategies; yet their effectiveness is limited and some drugs were taken off the market. Moreover, various surgical modalities, such as Roux-en-Y Bypass surgery, sleeve gastrectomy, intragastric balloons, biliopancreatic diversion with duodenal switch, laparoscopic adjustable gastric band, and vagal nerve blockade can be considered but are associated with numerous side effects and require careful monitoring.
View Article and Find Full Text PDFModel for Predicting the Effect of Sibutramine Therapy in Obesity.
J Pers Med
July 2024
Laboratory of Prediabetes and Metabolic Disorders, WCRC "Centre for Personalized Medicine", Almazov National Medical Research Centre, Saint Petersburg 197341, Russia.
The development of models predicting response to weight loss therapy using sibutramine is found in only a few cases. The objective of the work is to develop a data-driven method of personalized recommendation for obesity treatment that would predict the response to sibutramine based on the current set of patient parameters. The decision system is built on the XGBoost classification algorithm along with recursive feature selection and Shapley data valuation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!